









© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases 
Society of America. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original 
work is properly cited. 
Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: 
implications for COVID-19 epidemiology 
 
Summary: Human rhinovirus triggers an innate immune response that blocks SARS-CoV-2 
replication within the human respiratory epithelium. Given the high prevalence of human 
rhinovirus, this interference effect might cause a population-wide reduction in the number of 
new COVID-19 infections. 
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Abstract: Virus-virus interactions influence the epidemiology of respiratory infections. 
However, the impact of viruses causing upper respiratory infections on SARS-CoV-2 
replication and transmission is currently unknown. Human rhinoviruses cause the common 
cold and are the most prevalent respiratory viruses of humans. Interactions between 
rhinoviruses and co-circulating respiratory viruses have been shown to shape virus 
epidemiology at the individual host and population level. Here, we examined the replication 
kinetics of SARS-CoV-2 in the human respiratory epithelium in the presence or absence of 
rhinovirus. We show that human rhinovirus triggers an interferon response that blocks 
SARS-CoV-2 replication. Mathematical simulations show that this virus-virus interaction is 
likely to have a population-wide effect as an increasing prevalence of rhinovirus will reduce 
the number of new COVID-19 cases.  
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The rapid spread of COVID-19 and its impact on global health highlights the importance of 
viral respiratory diseases. The human respiratory tract hosts a community of viruses that 
includes members of the Orthomyxoviridae (e.g., influenza virus A and B), Pneumoviridae 
(e.g., respiratory syncytial virus), Picornaviridae (e.g., rhinovirus), Coronaviridae (e.g., 
severe acute respiratory syndrome coronavirus 2) and others [1, 2]. We and others showed 
that interactions between co-circulating, taxonomically different respiratory viruses, can 
influence patterns of infection [3, 4]. We showed that human rhinoviruses (HRVs) and 
influenza A viruses (IAVs) interact negatively at the individual patient and population level. 
Additionally, it has been postulated that the circulation of HRV delayed the spread of 
pandemic H1N1 influenza virus in France in 2009 [5]. Viral interference interactions at the 
host level are considered important in influencing observed population dynamics. Wu et al. 
demonstrated that HRV induces an interferon (IFN) response that protects against 
subsequent IAV infection in differentiated airway cultures [4], whereas Gonzalez et al. 
showed that RV attenuates influenza severity in a mouse model [6].  
Non-pharmacological interventions have hampered our ability to determine the impact of 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the epidemiology of 
respiratory viruses. However, it is possible that the emergence of SARS-CoV-2 will affect 
their ecology. Co-infection studies using air-liquid interface cultures of differentiated 
respiratory epithelial cells can shed light on the nature of SARS-CoV-2 interactions with 
other viruses and their effect on virus replication. Here, we examined the replication kinetics 
of SARS-CoV-2 in the presence of HRV in the human respiratory epithelium. HRV was 
selected due to i) its high prevalence in the human population [7]; ii) its negative interaction 
with IAV at the host and population level [3, 4]; iii) its ability to induce a strong IFN response 
[4]; and iv) the sensitivity of SARS-CoV-2 to IFN [8]. We used our experimental results as a 
proxy of within-host coinfection dynamics to simulate the impact of HRV circulation on the 























Primary human bronchial epithelial cells (HBEC) were sourced from Epithelix Sarl (Geneva, 
Switzerland).  Cells were maintained and seeded on transwells (Cell culture inserts, Falcon® 
Cat. No.: 734-0036) using Epithelix hAEC media (Epithelix, EP09AM) and incubated at 37oC 
with 5% CO2. An air-liquid interface (ALI) was initiated once they reached confluency, when 
the maintenance media was switched to PneumacultTM-ALI media (Cat. No.: 05001, 
STEMCELL Technologies). Vero E6 F5 cells were subcloned from Vero E6 cells, which were 
a gift from Prof. Michele Bouloy. A bulk population of VeroE6 cells was diluted in DMEM 
supplemented with 10% (v/v) foetal calf serum to 1 cell per 100 ul and plated into a 96 well 
format and incubated at 37C in a 5% CO2, humidified incubator. Wells were assessed for 
cell number with 0 and 3 cells/well observed.  Once the population had expanded, each 
clonal population was further seeded into a single well in a 96 well-plate. The next day, the 
plate was infected with 8400 pfu/well of SARS-CoV2 and left for 72 hours. The plates were 
fixed in 8% (w/v) formaldehyde in PBS and stained with Coomassie brilliant blue (0.1% [w/v] 
Coomassie Brilliant Blue R-250; 45% [v/v] methanol; 10% [v/v] glacial acetic acid) and 
assessed for cytopathic effect. Plates were scanned using a using the Celigo platform 
(Nexcelcom). Infection of 3 of 288 clones resulted in the clearance of the monolayer (2H6, 
5F3 and 6F5). These clones were further assessed for changes in plaque morphology, and 
whether the well-clearance assay generated representative titers. They were further 
assessed for growth characteristics.  Two of the three clones were discarded due and 
underestimate of virus titer (2H6) and longer mean generation time of the cells (5F2) in 
comparison the bulk population of VeroE6. HeLa Ohio cells were a gift from Dr. Toby Tuthill 
(The Pirbright Institute). Both cell lines were grown in Dulbecco's Minimum Essential Media 
(DMEM), high glucose, GlutaMAX supplemented with 10% fetal bovine serum (FBS) and 1% 























SARS-CoV-2 strain HCoV-19/England/02/2020 was sourced from Public Health England 
(GISAID accession: EPI_ISL_407073) originating from a clinical isolate and was passaged 
twice in VeroE6 cells. HRV-A16 was sourced from the American Type Culture Collection 
(ATCC) (ATCC VR-283).  
 
Infection of HBEC cultures 
Infection of HBECs. HBEC cultures were infected at ≥ 35 days post ALI initiation. The apical 
surface of the cultures was washed twice with serum free DMEM before infection (24 hours 
prior to infection and immediately before infection). Cells were inoculated with 104 PFU of 
either SARS-CoV-2 or HRV-A16, or a mixture containing 104 PFU of each virus and 
incubated at 37oC for 120 minutes. Previous experiments showed that inoculation of ALI 
cultures with 10,000 plaque forming units (PFU) resulted in consistent replication of HRV 
and SARS-CoV-2 [9]. The inoculum was removed, and cultures were washed once. This 
wash was titrated by 50% tissue culture infectious dose (TCID50) assay and served as the 0-
hour time point for growth curves. Cells were incubated at 37oC with 5% CO2. At each time 
point, serum free DMEM was added apically to each culture and incubated for 30 minutes at 
37oC. This was removed, aliquoted and stored at -80oC prior to subsequent titration. Each 
infection was carried out in two independent experiments and each experiment consisted of 
at least three technical replicates. Titrations of SARS-CoV-2 and HRV-A16 were performed 
on Vero E6 6F5 and HeLa OH cells, respectively. Virus samples were titrated in ten-fold 
serial dilutions in DMEM with 2% FBS and 1% NEAA on confluent monolayers of cells. Each 
sample was titrated in triplicate. SARS-CoV-2 TCID50 plates were incubated at 37
oC and 
HRV-A16 plates were incubated at 33oC. Plates were incubated for approximately 72 hours 
and fixed in 8% formaldehyde and stained with 0.1% Coomassie Brilliant Blue. Cytopathic 
effect was recorded, and a TCID50/ml titre determined as calculated by the Spearman and 





















PneumacultTM-ALI media containing 6 uM of BX795 (or DMSO) 18 hours prior to infection 
and media were changed daily. All experimental infections were carried out under Biosafety 
Level 3 conditions. 
 
Tissue processing and immunostaining 
After fixation in 8% formaldehyde for 16-24 hours, HBEC cultures were processed overnight 
for paraffin-embedding, sectioned to 2-3 µm-thick sections and mounted on glass slides.  
Two sections for each condition were sectioned and processed using pH 8 EDTA antigen 
retrieval and permeabilized with 1% triton. DAPI (Thermo Fisher Scientific, cat# P36392) 
was included in the mounting medium, and slides were stained with primary sheep anti-N 
(nucleocapsid) IgG antibody (DA114, mrcppu-covid.bio, 1: 1000 dilution), primary mouse 
anti-MxA antibody [11], primary mouse anti-VP2 antibody (QED Bioscience Ltd. – 18758), or 
a primary rabbit-anti-hACE2 (Cell Signalling Technology) antibody. For immunofluorescence, 
primary antibodies were detected using an AlexaFluor 555-conjugated donkey anti-sheep 
antibody (A11015, Thermo Fisher Scientific, 1:1000 dilution) and an AlexaFluor 488-
conjugated goat anti-mouse (Sigma SAB4600056, 1:1000 dilution). For 
immunohistochemistry, anti-hACE2 was detected using EnVision+ anti-rabbit HRP (Agilent 
K4003). IF sections were imaged using a Zeiss LSM880 confocal microscope and IHC 
sections were imaged with an Olympus BX51 microscope.  
 
Statistical analysis and data visualisation 
Statistical analysis and data visualisation were carried out in R 3.5.1 [12]. Multivariable 
logistic regression models were used to investigate significance among the different 
conditions. Those models accounted for biological replicates as this parameter was uneven, 
as well as treatment, and time post-infection. When biological replicate was not a significant 
parameter, this latter was removed to simplify the model. Models were run using the lme4 






















To determine if SARS-CoV-2 and HRV interact within the human respiratory epithelium, we 
infected air-liquid interface (ALI)-cultures of human bronchial epithelial cells (HBECs) with 
either SARS-CoV-2, HRV or with both viruses simultaneously. To assess the impact of 
coinfections on the replication kinetics of each virus, HRV and SARS-CoV-2 titers were 
determined at different times post infection from apical washes of coinfected cells and 
compared to their respective titers from single virus infections. SARS-CoV-2 exhibited highly 
contrasting replication kinetics in single and coinfections (p= 0.03928, Figure 1A). SARS-
CoV-2 titers increased slowly from 24 hours post-infection (hpi) onwards and up to 96 hpi in 
single infections, whereas in coinfections with HRV, SARS-CoV-2 titers decreased rapidly 
and were undetectable at 48 hpi (Figure 1A). In contrast, HRV titers displayed the same 
kinetics in single and coinfections: they increased rapidly during the first 24 hours, followed 
by a gradual and sustained decline (Figure 1B). As simultaneous coinfections might not 
occur frequently during natural infection, we performed staggered coinfections of ALI-
cultures of HBECs as follows: cells were infected with HRV, and 24 hours later they were 
infected with SARS-CoV-2. This experiment was also repeated in the reverse order (i.e., 
SARS-CoV-2 first, followed by HRV). As observed in simultaneous coinfections, SARS-CoV-
2 growth was severely impaired in both staggered coinfections: when SARS-CoV-2 
inoculation was followed by HRV infection (p= 0.0260) SARS-CoV-2 replication increased 
between 24 and 48 hpi as seen in SARS-CoV-2 single infection, but a subsequent sharp 
decrease was observed between 48 and 96 hpi (Fig, 1C). When HRV inoculation was 
followed by SARS-CoV-2 infection, SARS-CoV-2 replication did not exceed the inoculum 
titer and viral titers quickly declined (p= 0.0063) (Figure 1D). In contrast, the growth of HRV 
was unaffected by SARS-CoV-2 (p= 0.2027) regardless of the sequence order of infections 
(Figure 1C and 1D). When SARS-CoV-2 was inoculated first, the growth curve of HRV 
shifted and peaked at 72 hpi (Figure 1C), reflecting the delay in HRV inoculation. We tested 





















induced downregulation of the SARS-CoV-2 receptor, ACE2 [15]. To this end, we used 
immunohistochemistry to detect ACE2 in HRV or SARS-CoV-2 single infected and 
coinfected epithelial cells. We observed high levels of ACE2 expression on the apical 
surface of the epithelium regardless of the infection status of the cells (Figure S1) suggesting 
that HRV blocks SARS-CoV-2 infection via mechanisms that are independent of virus entry. 
SARS-CoV-2 is susceptible to IFN and encodes multiple genes that alter signaling pathways 
upstream and downstream of IFN production [8]. As HRV induces an interferon-mediated 
innate immune response that blocks IAV in ALI-cultures [4] we hypothesized that the 
observed block in SARS-CoV-2 replication was due to an HRV-triggered IFN response. To 
test this, we used fluorescence microscopy to examine the IFN-mediated innate immune 
activation induced by each virus. Specifically, we compared the in situ expression of MxA, a 
protein encoded by an IFN-stimulated gene that is highly upregulated upon IFN production 
[11]. Figure 2 shows that ALI-cultures of HBECs infected with HRV express high levels of 
MxA, contrasting with the low levels of MxA observed in SARS-CoV-2 infected cultures. 
Coinfected cultures exhibited high levels of MxA expression, similar to those exhibited in 
single infections with HRV (Figure 2). We further performed immunofluorescence using 
antibodies directed against the nucleocapsid (N) of SARS-CoV-2 and observed that N 
expression is clearly detected mainly on the apical area of epithelial cells subject to single 
SARS-CoV-2 infection, but undetectable in co-infected cells (Figure 3). Overall, our 
combined experiments confirmed i) that SARS-CoV-2 replication within the ALI-cultures of 
HBECs does not progress in the presence of HRV and ii) that HRV triggers a faster and 
likely stronger IFN response compared to SARS-CoV-2.  We therefore hypothesized that the 
block observed in SARS-CoV-2 replication was due to an innate immune response triggered 
by HRV. To test this, we performed HRV/SARS-CoV-2 coinfections in the presence of 
BX795, an inhibitor of TANK-binding kinase 1 that has been shown to block the IFN-
mediated innate immune response in differentiated cultures of respiratory epithelium [4]. In 





















restored to comparable levels to SARS-CoV-2 single infection, despite the presence of HRV 
(Figure 4A). This confirms that the observed block in SARS-CoV-2 replication in coinfections 
with HRV was the result of negative interactions driven by the innate immune response 
induced by HRV. Interestingly, HRV replication was also increased in the presence of BX795 
and titers plateau between 48 and 96 hpi, rather than declining as observed in the DMSO 
control coinfection and HRV single infection (Fig 4B). This indicates that virus-induced innate 
immune signaling also hampers HRV replication in HBECs. 
Given the high prevalence of HRV, we wanted to test if the observed within-host interference 
could have an impact on the number of new COVID-19 cases in the population. We 
performed mathematical simulations using the moment generating function equation [16] to 
derive the change in the growth rate of SARS-CoV-2 infections as a result from having a 
fraction of the population refractory to COVID-19 due to an episode of HRV infection (Data 
analysis S1 in Supplementary Material).  Our results show that the number of new SARS-
CoV-2 infections decreases as the number of HRV infections increase, and this reduction 
increases with higher HRV prevalences and longer duration of the interference effect (Figure 
5). When SARS-CoV-2 growth rates are low, HRV circulation can lead to SARS-CoV-2 
infections not spreading, whereas exponential growth is expected in the absence of HRV. 
 
Discussion 
Respiratory explants and ALI-cultures of human airway epithelium provide a highly controlled 
cellular environment that mimics to a considerable extent the natural site of infection and 
thus enables us to model the impact of virus tropism and innate immune responses on 
within-host infection dynamics [17]. Here we showed that HRV infection impairs SARS-CoV-
2 replication and spread within the human respiratory epithelium. Our study shows that HRV 
exerts an indirect negative interaction, with a dominant inhibitory phenotype against SARS-
CoV-2. Specifically, we showed that HRV triggers an IFN response that makes most cells 





















CoV-2. The susceptibility of SARS-CoV-2 to the IFN response is illustrated by the number of 
genes present in its genome that  are devoted to overcome the innate immune response 
(reviewed in [18]). We also showed that HRV hampers SARS-CoV-2 replication even when 
the former was inoculated 24 hours after SARS-CoV-2. Overall, our results demonstrate that 
viral interference interactions induced by HRV infection can inhibit SARS-CoV-2 replication 
in the respiratory epithelium and builds on previous epidemiological, modelling, and 
experimental work on virus-virus interactions [3-5, 19]. Future studies to elucidate the 
molecular mechanisms of viral interference could enable us to wield virus-virus interactions 
to our advantage and use them as control strategies or therapeutic measures. For example, 
screening for HRV-induced genes with anti-SARS-CoV-2 activity might constitute a future 
research avenue to develop antiviral therapies against coronaviruses. 
Recently, Wu et al. [4] showed that the IFN response triggered by HRV also interferes with 
IAV replication. Our combined studies suggest that viruses that stimulate an IFN response in 
the respiratory epithelium might interfere with SARS-CoV-2 and IAVs. These findings have 
important implications, as they suggest that immune-mediated effects induced by mild, 
common cold virus infections, including HRV, might confer some level of protection against 
SARS-CoV-2, potentially attenuating the severity of COVID-19. Given the high 
transmissibility and prevalence of HRV, this effect might have an impact on the disease 
burden caused by COVID-19 at the population scale, with expected heterogeneities 
depending on HRV prevalence among different age groups. For example, this interference 
effect can contribute to differences in SARS-CoV-2 transmission between school-aged 
children (with high prevalence of HRV) and adult populations (with comparatively lower HRV 
prevalence). 
Viruses are obligate intracellular pathogens that can only infect a restricted number of cell 
types within the body (a property known as tropism). Virus-virus interactions are likely to 
occur not only in the respiratory tract but also in other tissues that support multi-virus 





















the gut virome [20] and also affect the immunogenicity of the live attenuated polio vaccine 
[21]. The nature of such interactions (i.e., positive, negative, or neutral) is largely unknown 
and likely to be influenced by the specific viruses involved, the timing of each infection and 
the interplay between the host’s response to each virus. 
There is a vast body of knowledge on the impact of evolution on virus-host interactions [22-
25]. Many studies have focused on the evolutionary arms race between viruses and hosts, 
where the host’s immune system evolves antiviral mechanisms to stop viral replication and 
viruses evolve to evade antiviral proteins. We propose that virus-virus interactions influence 
this arms race and contribute to shaping their molecular interplay. For example, it is feasible 
to think that HRV infections in humans might be mutually beneficial: from a HRV perspective, 
humans evolved a tightly regulated immune response that allows HRV to replicate and 
transmit while it blocks other potentially competing viruses. From a host’s perspective, HRV 
infections, which are usually associated with mild disease, stimulate an antiviral response 
that prevents infections by more severe (and sometimes lethal) viruses such as SARS-CoV-
2 and IAV. Future studies using co-infections are needed to shed light on the role of ecology 
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Figure 1. Replication kinetics of SARS-CoV-2 and HRV in ALI-cultures of HBECs. (A) 
SARS-CoV-2 titers in single SARS-CoV-2 infections (solid red line) and simultaneous SARS-
CoV-2/HRV coinfections (dashed red line). (B) HRV titers in single HRV infections (solid 
cyan line) and simultaneous SARS-CoV-2/HRV coinfections (dashed cyan line). (C & D) 
SARS-CoV-2 (red) and HRV (cyan) titers in single infections (solid lines) and staggered 
SARS-CoV-2/HRV coinfections (dashed lines). The order of infections is described below 
each graph. SARS-CoV-2 is shown in red and HRV is shown in cyan. 
 
Figure 2. MxA expression in ALI-cultures of HBECs. Representative images of MxA 
expression by fluorescence microscopy at various times post infection. ALI-cultures were 
mock infected, infected with SARS-CoV-2 only, HRV only, and coinfected with SARS-CoV-2 
and HRV. Nuclei are colored in blue and MxA is colored in magenta. The scale bar indicates 
50 m. 
 
Figure 3. Detection of SARS-CoV-2 in ALI-cultures of HBECs. Representative images of 
SARS-CoV-2 N detection by immunofluorescence in cells infected with SARS-CoV-2 (A); co-
infected with SARS-CoV-2 and HRV (B); or mock infected (C). Nuclei are colored in blue and 
SARS-CoV-2 N protein is colored in red. The scale bar indicates 50 m. 
 
Figure 4. Replication kinetics of SARS-CoV-2 and HRV in ALI-cultures of HBECs coinfected 
simultaneously with SARS-CoV-2 and HRV in the presence or absence of BX795. (A) 
SARS-CoV-2 titers. (B) HRV titers. SARS-CoV-2 is shown in red and HRV is shown in cyan. 






















Figure 5. Reduction in COVID-19 growth rate for varying prevalence of rhinovirus infections 
in a given population and different assumptions for the duration of the refractory period. The 
growth rate in the absence of rhinovirus is assumed to be a 5% increase/day. Colors show 
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